{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T07:05:05Z","timestamp":1789974305404,"version":"4.0.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.vhri.2026.101646","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T20:04:46Z","timestamp":1779912286000},"page":"101646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cost-Effectiveness of Pharmaceutical Care in Reducing Type 2 Diabetes Complication Risks: A Biomarker-Based Economic Model"],"prefix":"10.1016","volume":"57","author":[{"given":"Price U.","family":"Price","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria O.","family":"Paganelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilia","family":"Silveira de Almeida Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo R.","family":"Leira Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vhri.2026.101646_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2024.1275167","article-title":"Predicting the prevalence of type 2 diabetes in Brazil: a modeling study","volume":"12","author":"Moreira","year":"2024","journal-title":"Front Public Health"},{"issue":"Suppl 1","key":"10.1016\/j.vhri.2026.101646_bib6","article-title":"Evolution of diabetes in Brazil: prevalence data from the 2013 and 2019 Brazilian National Health Survey","volume":"38","author":"Dos Reis","year":"2022","journal-title":"Cad Saude Publica"},{"issue":"1","key":"10.1016\/j.vhri.2026.101646_bib7","article-title":"Diabetes mellitus mortality trends in Brazil from 2000 to 2021: an in-depth joinpoint analysis","volume":"16","author":"McBenedict","year":"2024","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.vhri.2026.101646_bib8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11096-012-9710-7","article-title":"Pharmaceutical care program for type 2 diabetes patients in Brazil: a randomised controlled trial","volume":"35","author":"Mour\u00e3o","year":"2013","journal-title":"Int J Clin Pharm"},{"issue":"3","key":"10.1016\/j.vhri.2026.101646_bib9","first-page":"e1341","article-title":"Impact of Pharmaceutical Care on the clinical and healthcare parameters of individuals with type 2 Diabetes mellitus in primary care within Brazilian Public Health System","volume":"16","author":"Maria Ondina","year":"2025","journal-title":"J Hosp Pharm Health Serv"},{"key":"10.1016\/j.vhri.2026.101646_bib10","doi-asserted-by":"crossref","first-page":"6s","DOI":"10.11606\/S1518-8787.2017051007109","article-title":"Pharmaceutical care in Brazil\u2019s primary health care","volume":"51","author":"Ara\u00fajo","year":"2017","journal-title":"Rev Saude Publica"},{"issue":"1","key":"10.1016\/j.vhri.2026.101646_bib12","first-page":"3","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"7","author":"Husereau","year":"2022","journal-title":"MDM Policy Pract"},{"issue":"Suppl 1","key":"10.1016\/j.vhri.2026.101646_bib13","article-title":"6. Glycemic goals and hypoglycemia: standards of care in diabetes\u20142025","volume":"48","year":"2024","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1016\/j.vhri.2026.101646_bib14","first-page":"S6","article-title":"Executive summary: standards of medical care in diabetes\u20142009","volume":"32","year":"2009","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.vhri.2026.101646_bib15","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1161\/CIR.0000000000001040","article-title":"Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American heart association","volume":"145","author":"Joseph","year":"2022","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.vhri.2026.101646_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5493\/wjem.v4.i1.1","article-title":"High density lipoproteins and type 2 diabetes: emerging concepts in their relationship","volume":"4","author":"Kostapanos","year":"2014","journal-title":"World J Exp Med"},{"issue":"5","key":"10.1016\/j.vhri.2026.101646_bib17","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s10198-020-01167-y","article-title":"Health-related quality of life and health utilities in insulin-treated type 2 diabetes: the impact of related comorbidities\/complications","volume":"21","author":"Yfantopoulos","year":"2020","journal-title":"Eur J Health Econ"},{"issue":"4","key":"10.1016\/j.vhri.2026.101646_bib18","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jval.2014.03.003","article-title":"Review of utility values for economic modeling in type 2 diabetes","volume":"17","author":"Beaudet","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2026.101646_bib19","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1477-7525-8-18","article-title":"Health-related quality of life in diabetes: the associations of complications with EQ-5D scores","volume":"8","author":"Solli","year":"2010","journal-title":"Health Qual Life Outcomes"},{"issue":"7","key":"10.1016\/j.vhri.2026.101646_bib20","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s11136-007-9226-0","article-title":"Utilities and disutilities for type 2 diabetes treatment-related attributes","volume":"16","author":"Matza","year":"2007","journal-title":"Qual Life Res"},{"issue":"5","key":"10.1016\/j.vhri.2026.101646_bib21","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.3390\/ijerph110504939","article-title":"Health utilities of type 2 diabetes-related complications: a cross-sectional study in Sweden","volume":"11","author":"Kiadaliri","year":"2014","journal-title":"Int J Environ Res Public Health"},{"issue":"7","key":"10.1016\/j.vhri.2026.101646_bib28","first-page":"2643","article-title":"Self-reported diabetes and factors associated with it in the Brazilian adult population: National Health Survey, 2019","volume":"27","author":"Malta","year":"2022","journal-title":"Cien Saude Colet"},{"issue":"1","key":"10.1016\/j.vhri.2026.101646_bib29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1590\/1980-5497201700010002","article-title":"The prevalence of diabetes mellitus and its associated factors in the Brazilian adult population: evidence from a population-based survey","volume":"20","author":"Flor","year":"2017","journal-title":"Rev Bras Epidemiol"},{"issue":"1","key":"10.1016\/j.vhri.2026.101646_bib30","first-page":"345","article-title":"Differences in medical expenditures for men and women with diabetes in the medical expenditure panel survey, 2008\u20132016","volume":"1","author":"Williams","year":"2020","journal-title":"Womens Health Rep (New Rochelle)"},{"issue":"1","key":"10.1016\/j.vhri.2026.101646_bib31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.puhe.2004.03.004","article-title":"Gender differences in healthcare utilization and medical indicators among patients with diabetes","volume":"119","author":"Shalev","year":"2005","journal-title":"Public Health"},{"issue":"1","key":"10.1016\/j.vhri.2026.101646_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2458-13-1089","article-title":"Exploring differences in Canadian adult men and women with Diabetes management: results from the Canadian Community Health Survey","volume":"13","author":"De Melo","year":"2013","journal-title":"BMC Public Health"},{"issue":"1","key":"10.1016\/j.vhri.2026.101646_bib33","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s12913-017-2178-3","article-title":"Sex differences in healthcare expenditures among adults with diabetes: evidence from the medical expenditure panel survey, 2002-2011","volume":"17","author":"Williams","year":"2017","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"10.1016\/j.vhri.2026.101646_bib34","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1186\/s12916-024-03698-0","article-title":"Sex disparities in the prevalence, incidence, and management of diabetes mellitus: an Australian retrospective primary healthcare study involving 668,891 individuals","volume":"22","author":"Mnatzaganian","year":"2024","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.vhri.2026.101646_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.japh.2024.102253","article-title":"Cost-effectiveness of a pharmacist-led medication therapy management clinic for management of type 2 diabetes","volume":"65","author":"Joshi","year":"2025","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"3","key":"10.1016\/j.vhri.2026.101646_bib36","doi-asserted-by":"crossref","first-page":"10","DOI":"10.24926\/iip.v15i3.6300","article-title":"Cost-effectiveness analysis of pharmacist-led diabetes management across primary care clinics","volume":"15","author":"King","year":"2024","journal-title":"Innov Pharm"},{"issue":"2","key":"10.1016\/j.vhri.2026.101646_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.24926\/iip.v9i2.985","article-title":"Impact of pharmacist-led diabetes management in primary care clinics","volume":"9","author":"Pontefract","year":"2018","journal-title":"Innov Pharm"},{"issue":"1","key":"10.1016\/j.vhri.2026.101646_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12962-025-00651-7","article-title":"Cost-effectiveness analysis of a community pharmacist-based intervention to prevent cardiovascular complications in patients with type 2 diabetes in Iran","volume":"23","author":"Ghasemi","year":"2025","journal-title":"Cost Eff Resour Alloc"},{"issue":"5","key":"10.1016\/j.vhri.2026.101646_bib39","first-page":"652","article-title":"Underestimating the value of an intervention: the case for including productivity in value assessments and formulary design","volume":"26","author":"Karmarkar","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"issue":"8","key":"10.1016\/j.vhri.2026.101646_bib40","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.2337\/dc10-0843","article-title":"Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review","volume":"33","author":"Li","year":"2010","journal-title":"Diabet Care"},{"issue":"6","key":"10.1016\/j.vhri.2026.101646_bib41","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/dme.12651","article-title":"Adherence to diabetes medication: a systematic review","volume":"32","author":"Krass","year":"2015","journal-title":"Diabet Med"},{"issue":"9","key":"10.1016\/j.vhri.2026.101646_bib42","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness \u2014 The curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Eng J Med"},{"issue":"15","key":"10.1016\/j.vhri.2026.101646_bib43","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1001\/jama.2023.1792","article-title":"Cost-effectiveness thresholds used by study authors, 1990-2021","volume":"329","author":"Neumann","year":"2023","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.vhri.2026.101646_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0266934","article-title":"Estimating the range of incremental cost-effectiveness thresholds for healthcare based on willingness to pay and GDP per capita: a systematic review","volume":"17","author":"Iino","year":"2022","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.vhri.2026.101646_bib45","article-title":"A systematic review on the direct approach to elicit the demand-side cost-effectiveness threshold: implications for low- and middle-income countries","volume":"19","author":"Vu","year":"2024","journal-title":"PLoS One"},{"issue":"7160","key":"10.1016\/j.vhri.2026.101646_bib46","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1136\/bmj.317.7160.720","article-title":"Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40","volume":"317","author":"Gray","year":"1998","journal-title":"Br Med J"},{"issue":"14","key":"10.1016\/j.vhri.2026.101646_bib47","first-page":"1","article-title":"A systematic review and economic evaluation of statins for the prevention of coronary events","volume":"11","author":"Ward","year":"2007","journal-title":"Health Technol Assess (Rockv)"},{"issue":"5","key":"10.1016\/j.vhri.2026.101646_bib48","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2796.2008.02062.x","article-title":"Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials","volume":"265","author":"Pandor","year":"2009","journal-title":"J Intern Med"},{"issue":"6","key":"10.1016\/j.vhri.2026.101646_bib49","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jval.2025.01.001","article-title":"Screening for type 2 diabetes mellitus: a systematic review of recent economic evaluations","volume":"28","author":"Jin","year":"2025","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.vhri.2026.101646_bib50","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s40258-015-0198-x","article-title":"A systematic review of health economic evaluations of diagnostic biomarkers","volume":"14","author":"Oosterhoff","year":"2016","journal-title":"Appl Health Econ Health Policy"},{"issue":"3","key":"10.1016\/j.vhri.2026.101646_bib51","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s40291-023-00639-0","article-title":"A cost-effectiveness analysis of biomarkers for risk prediction in atrial fibrillation","volume":"27","author":"Nakhl\u00e9","year":"2023","journal-title":"Mol Diagn Ther"},{"issue":"1","key":"10.1016\/j.vhri.2026.101646_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12962-018-0105-z","article-title":"The early economic evaluation of novel biomarkers to accelerate their translation into clinical applications","volume":"16","author":"Graaf","year":"2018","journal-title":"Cost Eff Resour Alloc"},{"key":"10.1016\/j.vhri.2026.101646_bib53","first-page":"85","article-title":"\u2018Beyond the Mean\u2019 in biomarkers modelling for economic evaluations: a case study in gestational diabetes mellitus","volume":"297","author":"Nikolaidis","year":"2024","journal-title":"Contrib Econ Anal"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109926000610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109926000610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:54:36Z","timestamp":1789973676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109926000610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":42,"alternative-id":["S2212109926000610"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2026.101646","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Pharmaceutical Care in Reducing Type 2 Diabetes Complication Risks: A Biomarker-Based Economic Model","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2026.101646","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101646"}}